Platform · the engine
Our system for turning raw genomic signal into a decision a clinician can sign.
01The OnKommon Precision Intelligence Platform
Not a single algorithm, but a stack: an accredited generation layer, a curated knowledge substrate, a core interpretation engine, and six intelligence layers.
Every output is traceable, versioned, and handed to a human for the final word.
02
Laboratory partners sequence the tumour from blood or tissue, with transparent quality control and per-gene coverage.
It annotates every alteration, matches therapies and trials, and applies the six layers.
Licensed clinicians review, add judgement, author the narrative and sign.
The platform stack, layer by layer
03
At the core sits the OnKommon Interpretation Engine, working against OGID, our curated and versioned knowledge graph. OGID harmonises the leading evidence standards into one auditable framework, so every call is reproducible and every report states which knowledge version produced it.
Each variant classified for biological effect and cancer relevance.
Clinical significance graded against international frameworks.
Actionable alterations linked to therapies and recruiting studies.
Depth, tumour fraction and coverage carried through, so results are read in context.
04
Public databases say what a variant is. They cannot say how a tumour will evolve, whether the immune system can see it, or which combination is worth the toxicity.
Reconstructs which mutations are founder events present in every cancer cell versus later subclonal branches, and forecasts likely evolutionary paths. Targeting the trunk rather than a twig is one of the most important ideas in durable treatment.
Scores rational drug combinations for genuine added benefit against overlapping toxicity, as a net-benefit index, so combinations are proposed on evidence.
Places the tumour into its biological subtype, sharpening both treatment selection and prognostic context beyond single-gene findings.
Combines antigenicity, how visible the tumour is, with the integrity of the antigen-presentation machinery, whether it can hide, to estimate the real chance immunotherapy will work.
Matches the exact profile to recruiting trials, and situates the case against a real-world cohort of similar patients.
Maps each recommended therapy to clinically equivalent biosimilars, assistance programmes and schemes available in India.
05
One number for how targetable this cancer is.
A single 0 to 100 readout of how many high-quality, matched therapeutic options the biology supports. It is fast orientation for the clinician, never a substitute for the detailed evidence beneath it, which every report shows in full.
06
We do not invent our own significance scale. Where frameworks disagree, we show the disagreement rather than hide it.
| Framework | What it grades |
|---|---|
| AMP/ASCO/CAP tiers | Clinical significance of somatic variants, Tier I to IV. |
| ESCAT | How ready a molecular target is to guide treatment. |
| OncoKB levels | Therapeutic actionability by level of evidence. |
07
The platform is decision-support software. It informs a clinician, who decides. Our development follows recognised software-as-a-medical-device and clinical-AI good practice: versioned models, documented validation, transparent limitations, and human authorship of every consequential output through KPCIRC.
08
Accreditation and standards
Sequencing runs on high-throughput platforms in an accredited laboratory partner that is CAP-accredited and operates to ISO 15189. Variant calling, classification and reporting follow ACMG/AMP/ASCO/CAP guidelines using a CE-IVD certified variant database.
| Term | What it means |
|---|---|
| OPIP | The OnKommon Precision Intelligence Platform, the whole interpretation stack. |
| OGID | Our curated, versioned gene interpretation knowledge graph. |
| Oncogenicity | Whether a variant actually drives cancer biology. |
| Evidence tier | How strong the clinical evidence is for acting on a finding. |
| FHIR / mCODE | Healthcare data standards that let results integrate with clinical systems. |
| SaMD | Software as a medical device, the regulatory category for clinical software. |
Take the next step
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationCommission your decision report and a dedicated clinical team.
Explore Blueprint CareSignal replies to your first question within four hours, at no cost.
Start with Signal